1. Nayler, W.G., Classifications and tissue selectivity of calcium antagonists, Z. Kardio. 79, 3(1990)107–111.
2. Carpy, A., Leger, J.M. and Melchiorre, C., Structure of α-isopropyl-α-[(N-methyl-N-homoveratyl)-α-aminopropyl]-3,4-dimethoxyphenylacetonitrile hydrochloride, Verapamil C
27H38N2O4·HCl. Acta Crystallogr., C41(1985)624–627.
3. Maccotta, A., Scibona, G., Valensin, G., Gaggelli, E. and Botrè, F., Nuclear magnetic resonance investigations of calcium antagonists drug. II Conformational and dynamic features of Veramapil in [2H6] DMSO, J. Pharm. Sci., 80(1991)586–589.
4. Brasseur, R., Deleers, M. and Malaisse, W.J., Conformational analysis of the calcium antagonist, Gallopamil, Biochem. Pharmacol., 32(1983)437–440.
5. Mannhold, R, Bayer, R., Ronsdorf, M. and Martens, L., Comparative QSAR studies on vasodilatory and negative inotropic properties of ring-varied Verapamil congeners, Arzneim. Forsch./Drug Res., 37(1987)419–424.